Core Viewpoint - aTyr Pharma has appointed Dalia R. Rayes as Head of Commercial for the Global Efzofitimod Franchise, aiming to advance the commercialization of efzofitimod, a potential first treatment for pulmonary sarcoidosis in over 70 years [1][2]. Company Overview - aTyr Pharma is a clinical stage biotechnology company focused on developing first-in-class medicines from its proprietary tRNA synthetase platform, targeting therapies for fibrosis and inflammation [4]. - The lead therapeutic candidate, efzofitimod, is in clinical development for interstitial lung disease (ILD), which includes immune-mediated disorders causing lung inflammation and fibrosis [4]. Appointment Details - Dalia R. Rayes brings over 25 years of experience in biotechnology and pharmaceuticals, having led product launches in rare diseases [1][2]. - Ms. Rayes previously served as Senior Vice President at ChemoCentryx, where she developed the commercial strategy for TAVNEOS® prior to its acquisition by Amgen [2]. - She has also held significant roles at Actelion Pharmaceuticals, contributing to the launch of products like VALCHLOR® and OPSUMIT® [2]. Compensation Package - As part of her appointment, Ms. Rayes was granted an option to purchase 225,000 shares of aTyr's common stock at an exercise price of $3.49 per share, with a vesting schedule over four years [3].
aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise